(XRX) Xerox - Overview
Exchange: NASDAQ •
Country: United States •
Currency: USD •
Type: Common Stock •
ISIN: US98421M1062
Stock: Printers, Scanners, Copiers, Software
Total Rating 16
Risk 67
Buy Signal -2.01
| Risk 5d forecast | |
|---|---|
| Volatility | 71.0% |
| Relative Tail Risk | -10.6% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -1.42 |
| Alpha | -100.20 |
| Character TTM | |
|---|---|
| Beta | 1.954 |
| Beta Downside | 2.183 |
| Drawdowns 3y | |
|---|---|
| Max DD | 90.09% |
| CAGR/Max DD | -0.56 |
EPS (Earnings per Share)
Revenue
Risks
Technicals:
choppy
Description: XRX Xerox February 26, 2026
Xerox Holdings Corporation (NASDAQ:XRX) operates as a global workplace-technology firm, blending hardware, services, and software across two segments: Print & Other, and Xerox Financial Services (XFS). Its portfolio spans entry-level A4 printers, mid-range A3 multifunction devices, ConnectKey digital solutions, production presses, Managed Print Services, IT and content-capture offerings, as well as financing and leasing through XFS.
In its most recent fiscal quarter (Q2 2024), Xerox reported revenue of $2.03 billion, a 5.2% year-over-year increase driven by strong growth in Managed Print Services (+12%) and higher demand for workflow-automation software. The company’s adjusted operating margin improved to 8.1%, reflecting cost-discipline amid a broader corporate-spending slowdown. Macro-level, the shift toward remote work and digital-first initiatives continues to boost demand for integrated document-management solutions, a key sector driver for technology-hardware firms.
For a deeper dive into Xerox’s valuation and how these trends may affect its outlook, consider exploring additional analysis on ValueRay.
Piotroski VR‑10 (Strict, 0-10) 3.0
| Net Income: -1.03b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.03 > 0.02 and ΔFCF/TA -2.51 > 1.0 |
| NWC/Revenue: 5.40% < 20% (prev 5.08%; Δ 0.32% < -1%) |
| CFO/TA 0.04 > 3% & CFO 393.0m > Net Income -1.03b |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 1.12 > 1.5 & < 3 |
| Outstanding Shares: last quarter (128.0m) vs 12m ago 2.92% < -2% |
| Gross Margin: 36.83% > 18% (prev 0.32%; Δ 3651 % > 0.5%) |
| Asset Turnover: 77.23% > 50% (prev 74.37%; Δ 2.86% > 0%) |
| Interest Coverage Ratio: -1.97 > 6 (EBITDA TTM -157.0m / Interest Expense TTM 248.0m) |
Altman Z'' 0.62
| A: 0.04 (Total Current Assets 3.61b - Total Current Liabilities 3.23b) / Total Assets 9.82b |
| B: 0.25 (Retained Earnings 2.44b / Total Assets 9.82b) |
| C: -0.05 (EBIT TTM -488.0m / Avg Total Assets 9.09b) |
| D: -0.08 (Book Value of Equity -739.0m / Total Liabilities 9.15b) |
| Altman-Z'' Score: 0.62 = B |
Beneish M -3.16
| DSRI: 1.02 (Receivables 1.70b/1.47b, Revenue 7.02b/6.22b) |
| GMI: 0.86 (GM 36.83% / 31.51%) |
| AQI: 1.06 (AQ_t 0.60 / AQ_t-1 0.57) |
| SGI: 1.13 (Revenue 7.02b / 6.22b) |
| TATA: -0.14 (NI -1.03b - CFO 393.0m) / TA 9.82b) |
| Beneish M-Score: -3.16 (Cap -4..+1) = AA |
What is the price of XRX shares?
As of March 04, 2026, the stock is trading at USD 1.70 with a total of 3,568,996 shares traded.
Over the past week, the price has changed by -6.08%, over one month by -21.66%, over three months by -36.63% and over the past year by -72.18%.
Over the past week, the price has changed by -6.08%, over one month by -21.66%, over three months by -36.63% and over the past year by -72.18%.
Is XRX a buy, sell or hold?
Xerox has received a consensus analysts rating of 2.80.
Therefor, it is recommend to hold XRX.
- StrongBuy: 1
- Buy: 0
- Hold: 2
- Sell: 1
- StrongSell: 1
What are the forecasts/targets for the XRX price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 2.3 | 32.4% |
| Analysts Target Price | 2.3 | 32.4% |
XRX Fundamental Data Overview February 28, 2026
P/E Forward = 2.6069
P/S = 0.0324
P/B = 0.4239
P/EG = 0.1984
Revenue TTM = 7.02b USD
EBIT TTM = -488.0m USD
EBITDA TTM = -157.0m USD
Long Term Debt = 4.05b USD (from longTermDebt, two quarters ago)
Short Term Debt = 231.0m USD (from shortTermDebt, last quarter)
Debt = 4.25b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 3.73b USD (from netDebt column, last quarter)
Enterprise Value = 3.96b USD (227.6m + Debt 4.25b - CCE 512.0m)
Interest Coverage Ratio = -1.97 (Ebit TTM -488.0m / Interest Expense TTM 248.0m)
EV/FCF = 13.12x (Enterprise Value 3.96b / FCF TTM 302.0m)
FCF Yield = 7.62% (FCF TTM 302.0m / Enterprise Value 3.96b)
FCF Margin = 4.30% (FCF TTM 302.0m / Revenue TTM 7.02b)
Net Margin = -14.65% (Net Income TTM -1.03b / Revenue TTM 7.02b)
Gross Margin = 36.83% ((Revenue TTM 7.02b - Cost of Revenue TTM 4.44b) / Revenue TTM)
Gross Margin QoQ = 26.92% (prev 59.82%)
Tobins Q-Ratio = 0.40 (Enterprise Value 3.96b / Total Assets 9.82b)
Interest Expense / Debt = 1.88% (Interest Expense 80.0m / Debt 4.25b)
Taxrate = 21.0% (US default 21%)
NOPAT = -385.5m (EBIT -488.0m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 1.12 (Total Current Assets 3.61b / Total Current Liabilities 3.23b)
Debt / Equity = 6.45 (Debt 4.25b / totalStockholderEquity, last quarter 658.0m)
Debt / EBITDA = -23.79 (negative EBITDA) (Net Debt 3.73b / EBITDA -157.0m)
Debt / FCF = 12.37 (Net Debt 3.73b / FCF TTM 302.0m)
Total Stockholder Equity = 960.0m (last 4 quarters mean from totalStockholderEquity)
RoA = -11.32% (Net Income -1.03b / Total Assets 9.82b)
RoE = -107.2% (Net Income TTM -1.03b / Total Stockholder Equity 960.0m)
RoCE = -9.74% (EBIT -488.0m / Capital Employed (Equity 960.0m + L.T.Debt 4.05b))
RoIC = -8.15% (negative operating profit) (NOPAT -385.5m / Invested Capital 4.73b)
WACC = 2.08% (E(227.6m)/V(4.47b) * Re(13.12%) + D(4.25b)/V(4.47b) * Rd(1.88%) * (1-Tc(0.21)))
Discount Rate = 13.12% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 2.00%
[DCF] Terminal Value 86.71% ; FCFF base≈368.0m ; Y1≈382.2m ; Y5≈436.6m
[DCF] Fair Price = 71.80 (EV 12.97b - Net Debt 3.73b = Equity 9.23b / Shares 128.6m; r=5.90% [WACC]; 5y FCF grow 4.06% → 2.90% )
EPS Correlation: -38.76 | EPS CAGR: 0.96% | SUE: -1.89 | # QB: 0
Revenue Correlation: -5.77 | Revenue CAGR: 5.35% | SUE: -0.52 | # QB: 0
EPS next Quarter (2026-06-30): EPS=-0.01 | Chg7d=+0.036 | Chg30d=-0.149 | Revisions Net=-3 | Analysts=3
EPS current Year (2026-12-31): EPS=0.46 | Chg7d=+0.025 | Chg30d=-0.606 | Revisions Net=-3 | Growth EPS=+176.8% | Growth Revenue=+7.9%
EPS next Year (2027-12-31): EPS=1.16 | Chg7d=-0.186 | Chg30d=-0.186 | Revisions Net=-1 | Growth EPS=+151.1% | Growth Revenue=-1.1%
[Analyst] Revisions Ratio: -1.00 (0 Up / 3 Down within 30d for Next Quarter)
P/S = 0.0324
P/B = 0.4239
P/EG = 0.1984
Revenue TTM = 7.02b USD
EBIT TTM = -488.0m USD
EBITDA TTM = -157.0m USD
Long Term Debt = 4.05b USD (from longTermDebt, two quarters ago)
Short Term Debt = 231.0m USD (from shortTermDebt, last quarter)
Debt = 4.25b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 3.73b USD (from netDebt column, last quarter)
Enterprise Value = 3.96b USD (227.6m + Debt 4.25b - CCE 512.0m)
Interest Coverage Ratio = -1.97 (Ebit TTM -488.0m / Interest Expense TTM 248.0m)
EV/FCF = 13.12x (Enterprise Value 3.96b / FCF TTM 302.0m)
FCF Yield = 7.62% (FCF TTM 302.0m / Enterprise Value 3.96b)
FCF Margin = 4.30% (FCF TTM 302.0m / Revenue TTM 7.02b)
Net Margin = -14.65% (Net Income TTM -1.03b / Revenue TTM 7.02b)
Gross Margin = 36.83% ((Revenue TTM 7.02b - Cost of Revenue TTM 4.44b) / Revenue TTM)
Gross Margin QoQ = 26.92% (prev 59.82%)
Tobins Q-Ratio = 0.40 (Enterprise Value 3.96b / Total Assets 9.82b)
Interest Expense / Debt = 1.88% (Interest Expense 80.0m / Debt 4.25b)
Taxrate = 21.0% (US default 21%)
NOPAT = -385.5m (EBIT -488.0m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 1.12 (Total Current Assets 3.61b / Total Current Liabilities 3.23b)
Debt / Equity = 6.45 (Debt 4.25b / totalStockholderEquity, last quarter 658.0m)
Debt / EBITDA = -23.79 (negative EBITDA) (Net Debt 3.73b / EBITDA -157.0m)
Debt / FCF = 12.37 (Net Debt 3.73b / FCF TTM 302.0m)
Total Stockholder Equity = 960.0m (last 4 quarters mean from totalStockholderEquity)
RoA = -11.32% (Net Income -1.03b / Total Assets 9.82b)
RoE = -107.2% (Net Income TTM -1.03b / Total Stockholder Equity 960.0m)
RoCE = -9.74% (EBIT -488.0m / Capital Employed (Equity 960.0m + L.T.Debt 4.05b))
RoIC = -8.15% (negative operating profit) (NOPAT -385.5m / Invested Capital 4.73b)
WACC = 2.08% (E(227.6m)/V(4.47b) * Re(13.12%) + D(4.25b)/V(4.47b) * Rd(1.88%) * (1-Tc(0.21)))
Discount Rate = 13.12% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 2.00%
[DCF] Terminal Value 86.71% ; FCFF base≈368.0m ; Y1≈382.2m ; Y5≈436.6m
[DCF] Fair Price = 71.80 (EV 12.97b - Net Debt 3.73b = Equity 9.23b / Shares 128.6m; r=5.90% [WACC]; 5y FCF grow 4.06% → 2.90% )
EPS Correlation: -38.76 | EPS CAGR: 0.96% | SUE: -1.89 | # QB: 0
Revenue Correlation: -5.77 | Revenue CAGR: 5.35% | SUE: -0.52 | # QB: 0
EPS next Quarter (2026-06-30): EPS=-0.01 | Chg7d=+0.036 | Chg30d=-0.149 | Revisions Net=-3 | Analysts=3
EPS current Year (2026-12-31): EPS=0.46 | Chg7d=+0.025 | Chg30d=-0.606 | Revisions Net=-3 | Growth EPS=+176.8% | Growth Revenue=+7.9%
EPS next Year (2027-12-31): EPS=1.16 | Chg7d=-0.186 | Chg30d=-0.186 | Revisions Net=-1 | Growth EPS=+151.1% | Growth Revenue=-1.1%
[Analyst] Revisions Ratio: -1.00 (0 Up / 3 Down within 30d for Next Quarter)